Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Moxibustion in SR-aGVHD After Allo-HSCT
NCT07572669Phase 2Recruiting
- Start
- Sep 2025
- Primary completion
- Mar 2027
- Countries
- 1
01
Overview
Phase 2, open-label trial in Acute Graft-Versus-Host Disease (aGvHD) (2 arms). Primary endpoint: Overall Response Rate at 28 days. Started Sep 2025; status: recruiting.
02
Conditions
Acute Graft-Versus-Host Disease (aGvHD)
Beyond the preview
Go deeper on NCT07572669.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07572669.